Stoke Therapeutics (STOK) Change in Cash (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Change in Cash of $74.4 million for Q1 2026, down 49.3% year-over-year from $146.8 million in Q1 2025, and up 8911.99% quarter-over-quarter from $826000.0 in Q4 2025.
Powered by 
Analysis
Stoke Therapeutics (STOK) Change in Cash (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Change in Cash history runs 9 years deep, the most recent figure standing at $74.4 million for Q1 2026.
- In Q1 2026, Change in Cash fell 49.3% year-over-year to $74.4 million; the TTM figure through Mar 2026 stood at -$116.2 million (down 220.5% YoY), while the FY2025 annual figure was -$43.8 million, up 30.67% from the prior year.
- Change in Cash for Q1 2026 stood at $74.4 million, up from $826000.0 in the prior quarter.
- The five-year high for Change in Cash was $146.8 million in Q1 2025, with the low at -$173.3 million in Q2 2025.
- The 5-year median for Change in Cash is $160000.0 (2022), against an average of $818588.2.
- The sharpest annual moves came in 2024 and 2025: Change in Cash tumbled 1986.41% in 2024, then jumped 1241.69% in 2025.
- Stoke Therapeutics' Change in Cash stood at $160000.0 in 2022, then surged by 815.62% to $1.5 million in 2023, then plunged by 1588.46% to -$21.8 million in 2024, then jumped by 103.79% to $826000.0 in 2025, then soared by 8911.99% to $74.4 million in 2026.
- Business Quant data shows STOK's Change in Cash at $74.4 million in Q1 2026, $826000.0 in Q4 2025, and -$18.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -185.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 427.25 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | -2.94 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | -45.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -45.66 Mn |
| Mar 31, 2026 | 74.44 Mn |
| Dec 31, 2025 | 826,000.00 |
| Sep 30, 2025 | -18.15 Mn |
| Jun 30, 2025 | -173.35 Mn |
| Mar 31, 2025 | 146.83 Mn |
| Dec 31, 2024 | -21.81 Mn |
| Sep 30, 2024 | -43.46 Mn |
| Jun 30, 2024 | 14.90 Mn |
| Mar 31, 2024 | -12.86 Mn |
| Dec 31, 2023 | 1.47 Mn |
| Sep 30, 2023 | -2.08 Mn |
| Jun 30, 2023 | 1.72 Mn |
| Mar 31, 2023 | 76.78 Mn |
| Dec 31, 2022 | 160,000.00 |
| Sep 30, 2022 | 45.64 Mn |
| Jun 30, 2022 | -16.36 Mn |
| Mar 31, 2022 | -60.78 Mn |
| Dec 31, 2021 | -4.29 Mn |
| Sep 30, 2021 | -19.54 Mn |